Introduction
Oral controlled release drug delivery systems can be classified in two broad groups 1. Single unit dosage forms (SUDFs) , such as tablets or capsules , and 2. Multiple unit dosage forms (MUDFs), such as granules, pellets or minitablets. Single unit: Single unit dosage forms include matrix tablet or coated/uncoated tablet or capsules and consist of only one unit, e.g. osmotic tablet.
Multiple-unit:
The basic concept of multiple-unit systems is that the dose of the active ingredient is released by the individual subunits (like, pellets, minitablets), and the functionality of the entire dose depends on the quality of the subunits [1] . Advantages of multiple unit dosage forms 1 . Local irritation and side effects are reduced and more consistent plasma levels are achieved (2) . 2. Coated MUDFs prevents the risk of dose dumping due to the use of multiple particles. 3. The combination of different multiple particles may reduce the daily required number of drugs, which can improve patient compliance. 4. MUDFs may seem costlier than SUDFs in the short term; but causes significant savings, lower treatment failure rate, lower case-fatality ratios, reduction in development of resistance, more predictable gastric emptying and consequently less money needed for the development of new products in long term therapy [3] . Disadvantages of multiple unit dosage forms 1 . The main disadvantage of MUDFs is the complex production process. 2. MUDFs can be bigger in volume than tablets which can effect patient compliance.
Minitablets [4]
Mini tablets are flat or curved tablets with a 1.0-3.0 mm diameter which, for pharmaceutical use, are normally filled in hard gelatine capsules Mini tablets can be an alternative to normally sized tablets, if there are specific preparation requirements as regards the following aspects:  Release profile/ drug absorption  Constituents  A comparison of pellets/ mini tablets
Encapsulated biphasic minitablets
Encapsulated biphasic mini tablet system is aimed to reduce the size of the tablet such that it can be enclosed in a capsule, and then deploy tablets with different release properties within the one encapsulated mini tablet. This biphasic system comprises of immediate release mini tablets (IRMT) and sustained release mini tablets (SRMT) in a hard gelatine capsule. These mini tablets can also be filled in HPMC capsule. The main objective of this study is to achieve desired target product profile (DPP) for a period of 12 hours. Biphasic delivery systems are designed to release a drug at two different rates or in two different periods of time: they are either quick/slow or slow/quick. A quick/slow release system provides an initial burst of drug release followed by a constant rate (ideally) of release over a defined period of time and in slow/quick release system provides release vice versa [7] . Several approaches have been proposed to retain the dosage forms in the stomach. These methods include bioadhesive system, swelling system and expanding system and floating system. Gastroretentive drug delivery systems (GRDDS) can improve the controlled delivery of drugs that have an absorption window by continuously releasing the drug for a prolonged period of time before it reaches its absorption site thus ensuring its optimal bioavailability [8, 9] . Floating mini tablets -Floating drug delivery system (FDDS) possesses a bulk density lower than gastric fluids and thus remain buoyant in the gastric fluids for a prolonged period without affecting the gastric emptying rate. While the system is floating on the gastric content, the drug released slowly at desired rate from the system [10] .Based on the mechanism of buoyancy, two distinctly different technologies, non-effervescent and effervescent systems have been utilized in the development of FDDS. In effervescent systems a gas generating agent usually sodium bicarbonate or sodium carbonate is mixed with matrices prepared with swellable polymers, when the systems comes in contact with gastric fluids, the carbondioxide is liberated by the acidity of gastric contents and the gas is entrapped in the viscous hydrocolloid. Thus produces an upward motion of the system maintaining buoyancy [11] .
Repaglinide
It is the first member of the class of oral hypoglycaemics designed to normalize the meal time glucose excursions. It is administered before each major meal to control postprandial hyperglycemia; the dose may be omitted if a meal is missed. Because of short lasting action it may have a lower risk of serious hypoglycemia. Side effects are mild headache, dyspepsia, arthralgia, and weight gain. After oral administration, Repaglinide is rapidly and completely absorbed from the gastrointestinal tract. Repaglinide is a white to off-white powder with molecular formula C 27 H 36 N 2 O 4 and a molecular weight of 452.6, poorly soluble in water. Its having half-life (0.9-1 hour) and usually administered with a starting dose of 0.5mg before each meal as immediate release tablets . The maximum tolerable dose of Repaglinide is 16mg per day. The blood level fluctuation resulting from this frequent administration leads to extrpyramidal symptoms.
Literature review
D. Karthikeyan et al., [1] Investigated the feasibility of formulating a biphasic delivery system using mini-tablets in hard gelatin capsules delivering drug with a variety of release profiles. Aceclofenac (NSAID analgesic) were chosen as model drug. Immediate release minitablets (IRMT) were manufactured by direct compression using microcrystalline cellulose and cross carmellose as a superdisintegrant, each mini-tablet containing approximately 25 mg Aceclofenac (AFC). Sustained release mini-tablets (SRMT) were formulated using various ratios of HPMC K4M and HPMC K100M. Capsules were filled with individual mini-tablets to deliver 100 mg of AFC. The IR and SRMT were combined in the capsule designed to provide a pulsatile or multi-phase delivery of drug as immediate and sustained dissolution release profiles. Capsules containing AFC immediate release mini-tabs were shown to release nearly 100% of the drug within 60 minutes. Capsules containing SRMT released 98 % of AFC over 12 hours. The feasibility of delivering a drug in biphasic immediate sustained release manner was reputable by combining mini-tablets in a hard gelatin capsule.
Noorana Tehseen et al., [2] worked on design and characterization of twice daily mini-tablets formulation of pregabalin in order to improve the half life and bioavailability. The system comprises of 15 matrix mini-tablets weighing 25 mg encapsulated in HPMC capsule (size1). For achieving the sustain release profile, various viscosity grades of Hydroxy propyl methyl cellulose polymer (HPMC K4M, K15M, K100M) were used. The mini-tablets were prepared by direct-compression method. The prepared mini-tablets were subjected for pre-compressional and post-compressional parameters. The compatibility of drug with other ingredients was checked by FTIR studies. Stability study carried out as per ICH guidelines for three months.
Carla M. Lopes et al., [3] developed compressed mini tablets as a biphasic delivery system designed for zero-order sustained drug release. The outer layer that fills the void spaces between the mini-tablets was formulated to release the drug in a very short time (fast release), while the mini-tablets provided a prolonged release. Different composition (HPMC or EC) and number (10 or 21) of mini-tablets were used to obtain different drug release rates. The in vitro performance of these systems showed the desired biphasic behaviour: the drug contained in the fast releasing phase (powder enrobing the mini-tablets) dissolved within the first 2 min, whereas the drug contained in the mini-tablets was released at different rates, depending up on formulation.
Based on the release kinetic parameters calculated, it can be concluded that mini-tablets containing HPMC were particularly suitable approaching to zero-order (constant) release over 8 h time periods.
Jitender Joshi et al., [4] developed a once-daily sustained release matrix tablet of Repaglinide using sodium alginate as release controlling factor. In order to achieve required sustained release profile tablets were compressed using sodium CMC, sodium alginate, Magnesium Stearate, and PVP. Six different formulation of Repaglinide were prepared by using different ratio of drug: polymer. The tablet was characterized by hardness, wetting time, weight variation and In Vitro Drug Release which shows the satisfactory result. All batches of solid matrix tablets were satisfactory in terms of dissolution profile. The batches of all formulations, MT5 batch [Sodium CMC With drug (1:3)] showed more release than the other concentration and better results. The MT5 batch of Solid matrix tablets was found to be 96.0 % drug release in 300 minutes.
Objectives of the study
The objective of this work was the formulation and invitro evaluation of biphasic mini tablets of Repaglinide.
II. Materials & Methodology
Materials : Repaglinide,magnesium stearate, talc, lactose, cross povidone, sodium starch glycolate, cross carmellose sodium, micro crystalline cellulose, HPMC K4M, HPMC K15M, HPMC K100M, ethyl cellulose, sodium bicarbonate.
Preformulation study Scanning of Repaglinide in 0.1 N HCl
The solution containing 100 µg/ml of Repaglinide in 0.1 N HCl was prepared and scanned over the wavelength of 200-400 nm against 0.1N HCl as blank using double beam UV spectrophotometer. The plot of absorbance vs wavelength was recorded using double beam UV spectrometer.
Drug -Excipients interaction study FTIR Spectroscopy:
The study was performed by taking 1mg sample in 200 mg KBr. The mixture was taken in a diffuse reflectance sampler and the spectrum was recorded by scanning in the wavelength region of using FTIR instrument.
Formulation of immediate release mini tablets:
Tablets were prepared by direct compression method.
Table1: Composition of immediate release Repaglinide mini tablets IF1-IF6 (Direct Compression)
Ingredients IF1  IF2  IF3  IF4  IF5  IF6  Drug  2  2  2  2  2  2  SSG  10  20  ----CP  --10  20  --CCS  ----10  20  Mag.stearate  2  2  2  2  2  2  Talc  2  2  2  2  2  2  Lactose  37  12  37  12  37  12 Total wt. 50 50 50 50 50 50 SF1  4  25  --2  2  10  37  80  SF2  4  50  --2  2  10  12  80  SF3  4  -25  -2  2  10  37  80  SF4  4  -50  -2  2  10  12  80  SF5  4  25  25  -2  2  10  12  80  SF6  4  -60  -2  2  10  2  80  SF7  4  --60  2  2  -2  80  SF8  4  -30  30  2  2  -2  80  SF9  4  ---2  2  -2  80  SF10  4  -30  -2  2  -2  80  SF11  4  --30  2  2  -2  80 SSG -sodium starch glycolate; CP-cross povidone; CCS-cros carmellose sodium; mag,st-magnesium stearate
Evaluation of biphasic mini tablets of Repaglinide Precompression parameters
The granules were evaluated for bulk density, tapped density, Carr's index, Hausner's ratio and angle of repose. Post compression parameters: The prepared sustained release and immediate release mini tablets were evaluated for thickness, hardness, weight variation test, invitro release study and determination of buoyancy lag time ,total floating time and swelling index .
III.
Results 
Evaluation of tablets Post compression parameters:
The evaluation parameters like thickness, hardness, friability and weight variation of immediate and sustained release formulations are indicated in Table 4 , 5. 
Drug release Kinetics
Table10: Model fitting for formulation optimised sustained release formulation SF11 Figure 6 : Model fitting for formulation optimised sustained release formulation SF11 The mechanism of drug release for the optimized mini tablet formulation was based on regression coefficient (r2) value. From the Table 10 it can be concluded that the drug release followed first order model Fig. 6 .
IV. Conclusion
In the present study, an attempt was made to develop a biphasic mini tablets in a capsule system containing immediate and floating sustained release mini tablet. Because of their physical characteristics, minitablets tend to keep their integrity after compression, making more difficult the fracturing process of these subunits.
IF2 was optimised in (IRMT) immediate release minitablet containing SSG as a super disintegrating agent and SF11 was optimised in (SRMT) sustained release minitablet containing HPMC K100M and Ethyl cellulose along with other common tablet excipients to control as well as extend the drug release over a period of 10 hrs. The optimised mini tablets placed in a capsule showed satisfactory results in several in vitro tests. Number of mini tablets can be filled depending upon the size of the capsule shell and the diameter or weight of mini-tablets.
